SCHEMBL20818979

SCHEMBL20818979

COc1cccc2oc(C(C(=O)O)C(=O)O)nc12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EDNRA P25101 1/20 0.43
KMT2A Q03164 4/20 0.43
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 2/20 0.43
KDM4E B2RXH2 2/20 0.43
HPGD P15428 2/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43
CA12 O43570 2/20 0.40
CA1 P00915 2/20 0.40
CA2 P00918 2/20 0.40
CA7 P43166 2/20 0.40
CA9 Q16790 2/20 0.40
CA14 Q9ULX7 2/20 0.40
F2RL3 Q96RI0 2/20 0.39
PDE10A Q9Y233 1/20 0.39
CA3 P07451 1/20 0.38
CA4 P22748 1/20 0.38
CA6 P23280 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20931268 0.84 F2RL3 (0.41) EDNRAKMT2AALDH1A1MEN1KDM4E
SCHEMBL20836961 0.81 F2RL3 (0.39) EDNRAKMT2AALDH1A1MEN1KDM4E
SCHEMBL6955824 0.81 ALDH1A1 (0.43) EDNRAKMT2AALDH1A1MEN1KDM4E
SCHEMBL22439323 0.80 ALDH1A1 (0.45) KMT2AALDH1A1MEN1KDM4EHPGD
SCHEMBL20837403 0.76 VCP (0.36) EDNRAKMT2AALDH1A1MEN1KDM4E
SCHEMBL20837409 0.76 MEN1 (0.35) EDNRAKMT2AALDH1A1MEN1KDM4E
SCHEMBL6958263 0.75 LMNA (0.47) EDNRAKMT2AALDH1A1MEN1KDM4E
SCHEMBL20837401 0.74 CYP3A4 (0.34) EDNRAKMT2AALDH1A1MEN1KDM4E
SCHEMBL20931281 0.72 ELANE (0.49) EDNRAKMT2AALDH1A1MEN1KDM4E
SCHEMBL9768577 0.72 NQO2 (0.46) EDNRAKMT2AALDH1A1MEN1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 US disclosed
EP-3681888-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF Aduro Biotech, Inc. (US) 2020-07-22 EP disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 US disclosed
WO-2019055750-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF Aduro Biotech, Inc. (US) 2019-03-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 EDNRA 3924/4885KMT2A 3490/4885ALDH1A1 1246/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 EDNRA 3924/4885KMT2A 3490/4885ALDH1A1 1246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.